Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis

Lyme Diagnostics

Status: Completed

Conditions: Lyme Borreliosis

Treatments: Diagnostic Test: DualDur Polymerase chain reaction; Diagnostic Test: DualDur dark-field automatic microscopic test; Diagnostic Test: enzyme-linked immunosorbent assay (ELISA) IgM and IgG; Diagnostic Test: Bózsik Western blot IgM and IgG; Diagnostic Test: DualDur dark-field microscopic test; Diagnostic Test: Western blot IgM and IgG

Study type: Observational

Funder types: Industry

Identifiers

NCT03873974

LymeDD_CIP

Details and patient eligibility

About

The clinical data from the clinical trial will be used to assess the performance, sensitivity and specificity of the experimental DualDur In Vitro Diagnostic System.

Full description

The clinical data from the clinical trial will be used to assess the performance, sensitivity and specificity of the experimental DualDur In Vitro Diagnostic System.

• The sensitivity of the DualDur in Vitro Diagnostic System will be examined in subjects whose physician indicates drug therapy for Lyme borreliosis (positive arm).
• The specificity of the DualDur in Vitro Diagnostic System will be examined in healthy volunteers declared Lyme borreliosis negative by their physician and all the standard laboratory tests prove that they are free of Lyme borreliosis (negative arm).

The diagnostic system developed by Lyme Diagnostics Ltd. is planned for application in the diagnosis during the entire life cycle of Lyme borreliosis.

Enrollment: 400 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

I. Positive trial arm

I.1. Inclusion Criteria:

• Man or female subjects over 18 years of age
• Treatment-naive or treatment-experienced subjects with Lyme borreliosis, whose physician indicates drug therapy for Lyme borreliosis.
• Subjects capable of reading, understanding, and observing the requirements of the clinical trial, who sign the Patient Information Leaflet and Informed Consent Form approved by the Competent Authority and the Ethics Committee.

I. 2. Exclusion Criteria:

• Man or female subjects over 80 years of age
• Pregnancy, breastfeeding
• History of any complication related to previous blood sampling
• Coagulation and/or bleeding disorders
• Anticoagulant therapy
• Acute, life-threatening condition
• Participation in another clinical trial
• The patient is under antibiotic therapy, or received such treatment in the preceding 3 months
• The patient is currently taking or has taken in the preceding 6 months dietary supplements of herbal origin, or medicinal herbs as first-line or add-on treatments for Lyme borreliosis
• In the event the patient has previously been treated for Lyme borreliosis, then this treatment took place less than 6 months before blood sampling.
• In the preceding 6 months, the patient used an electronic device operating along the principle of electromagnetic (i.e. electric or magnetic) fields - such as bioresonance, pulsed magnetic field, etc. - as add-on treatment for Lyme borreliosis.

II. Negative trial arm

II.1. Inclusion Criteria:

• Man or female subjects over 18 years of age
• Asymptomatic healthy volunteer subjects without acute or chronic symptoms of Lyme borreliosis, who are free of Lyme borreliosis by the indication of all standard laboratory tests, and who are willing to take part in a comprehensive medical examination and related blood sampling.
• Subjects capable of reading, understanding, and observing the requirements of the trial, who sign the Patient Information Leaflet and Informed Consent Form approved by the Competent Authority and the Ethics Committee.

II. 2. Exclusion Criteria:

• Man or female subjects over 80 years of age
• Pregnancy, breastfeeding
• History of any complication related to previous blood sampling
• Coagulation and/or bleeding disorders
• Anticoagulant therapy
• Participation in another clinical trial
• Lyme borreliosis diagnosed previously, at any time during the life of the subject
• The subject has received any treatment for Lyme borreliosis (medicinal products, dietary supplements, medicinal plants, electronic devices, etc.) during his/her life
• The patient is under antibiotic therapy, or received such treatment in the preceding 3 months
• The occupation of the subject is either a forester or a hunter

Trial design

400 participants in 2 patient groups

Negative trial arm

Description:

Venous blood samples will be taken for central laboratory analysis with: * DualDur dark-field microscopic test * DualDur dark-field automatic microscopic test * Western blot IgM and IgG * Bózsik Western blot IgM and IgG * Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG * DualDur Polymerase chain reaction

Treatment:

Diagnostic Test: Bózsik Western blot IgM and IgG

Diagnostic Test: enzyme-linked immunosorbent assay (ELISA) IgM and IgG

Diagnostic Test: Western blot IgM and IgG

Diagnostic Test: DualDur dark-field microscopic test

Diagnostic Test: DualDur dark-field automatic microscopic test

Diagnostic Test: DualDur Polymerase chain reaction

Positive trial arm

Description:

Venous blood samples will be taken for central laboratory analysis with: * DualDur dark-field microscopic test * DualDur dark-field automatic microscopic test * Western blot IgM and IgG * Bózsik Western blot IgM and IgG * Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG * DualDur Polymerase chain reaction

Treatment:

Diagnostic Test: Bózsik Western blot IgM and IgG

Diagnostic Test: enzyme-linked immunosorbent assay (ELISA) IgM and IgG

Diagnostic Test: Western blot IgM and IgG

Diagnostic Test: DualDur dark-field microscopic test

Diagnostic Test: DualDur dark-field automatic microscopic test

Diagnostic Test: DualDur Polymerase chain reaction